Clinical Trial Update: Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of exemestane (Aromasin) in patients with recurrent or refractory stage II-IV epithelial ovarian cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Aromasin (exemestane)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED